Zogenix, Inc. (ZGNX) Director Sells $2,328,398.52 in Stock
Zogenix, Inc. (NASDAQ:ZGNX) Director Roger Hawley sold 63,203 shares of Zogenix stock in a transaction on Monday, December 11th. The stock was sold at an average price of $36.84, for a total value of $2,328,398.52. Following the completion of the sale, the director now directly owns 105,575 shares of the company’s stock, valued at approximately $3,889,383. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Roger Hawley also recently made the following trade(s):
- On Friday, December 8th, Roger Hawley sold 11,797 shares of Zogenix stock. The stock was sold at an average price of $37.02, for a total value of $436,724.94.
Zogenix, Inc. (NASDAQ ZGNX) opened at $37.00 on Thursday. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.23. Zogenix, Inc. has a 52-week low of $7.70 and a 52-week high of $42.60.
Several analysts recently commented on the company. Mizuho reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Zogenix in a report on Thursday, December 7th. JMP Securities assumed coverage on Zogenix in a research report on Monday, November 27th. They set an “outperform” rating and a $56.00 target price on the stock. Leerink Swann reiterated an “outperform” rating and set a $50.00 target price (up from $20.00) on shares of Zogenix in a research report on Monday, October 2nd. ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $55.00 target price (up from $26.00) on shares of Zogenix in a research report on Friday, September 29th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Zogenix has a consensus rating of “Buy” and a consensus target price of $42.67.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Stock Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related stocks with our FREE daily email newsletter.